Trial report in Circulation. Cardiovascular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01347710 (A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography), which is not on this map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Flurpiridaz F18 Injection in Patients With Suspected or Known Coronary Artery Disease (CAD)
TypeinterventionalSponsorLantheus Medical ImagingRan2011 to 2013Enrolled795ConditionsCoronary Artery DiseaseArmsFlurpiridaz F18, 99mTechnicium (sestamibi or tetrofosmin)
Diana M LopezCardiovascular Imaging Program, Departments of Medicine and Radiology (D.M.L., D.M.H., S. Divakaran, J.M.B., B.N.W., S. Dorbala, R.B., M.F.D.C.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0001-6335-9625
Daniel M HuckCardiovascular Imaging Program, Departments of Medicine and Radiology (D.M.L., D.M.H., S. Divakaran, J.M.B., B.N.W., S. Dorbala, R.B., M.F.D.C.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-4221-8078
Sanjay DivakaranCardiovascular Imaging Program, Departments of Medicine and Radiology (D.M.L., D.M.H., S. Divakaran, J.M.B., B.N.W., S. Dorbala, R.B., M.F.D.C.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-0598-6502
Jenifer M BrownCardiovascular Imaging Program, Departments of Medicine and Radiology (D.M.L., D.M.H., S. Divakaran, J.M.B., B.N.W., S. Dorbala, R.B., M.F.D.C.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-6647-639X
Brittany N WeberCardiovascular Imaging Program, Departments of Medicine and Radiology (D.M.L., D.M.H., S. Divakaran, J.M.B., B.N.W., S. Dorbala, R.B., M.F.D.C.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-0177-2091
Mark LemleyDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA (M.L., V.B., A.S., P.S.).ORCID 0000-0002-1531-880X
Valerie BuiloffDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA (M.L., V.B., A.S., P.S.).
Aakash ShanbhagDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA (M.L., V.B., A.S., P.S.).ORCID 0000-0001-5199-3071
Zhou LanDepartment of Radiology (Z.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Christopher BuckleyGE Healthcare, Pharmaceutical Diagnostics, Buckinghamshire, United Kingdom (C.B.).
Mouaz H Al-MallahHouston Methodist DeBakey Heart and Vascular Center, TX (M.H.A.-M.).ORCID 0000-0003-2348-0484
Sharmila DorbalaCardiovascular Imaging Program, Departments of Medicine and Radiology (D.M.L., D.M.H., S. Divakaran, J.M.B., B.N.W., S. Dorbala, R.B., M.F.D.C.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-1462-1185
Ron BlanksteinCardiovascular Imaging Program, Departments of Medicine and Radiology (D.M.L., D.M.H., S. Divakaran, J.M.B., B.N.W., S. Dorbala, R.B., M.F.D.C.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-8393-6562
Piotr Slomka *Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA (M.L., V.B., A.S., P.S.).ORCID 0000-0002-6110-938X
Marcelo F Di Carli *Cardiovascular Imaging Program, Departments of Medicine and Radiology (D.M.L., D.M.H., S. Divakaran, J.M.B., B.N.W., S. Dorbala, R.B., M.F.D.C.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-3119-025X
Funding
Harvard Clinical and Translational Science CenterUM1TR004408 · NCATS · HARVARD MEDICAL SCHOOL · PI Lindsey Robert Baden, Lee Marshall Nadler · 2023 to 2026
$43.3M
TUFTS--FIELDINGP30AG031679 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI Ravi Jasuja · 2008 to 2026
$23.9M
Patient-specific Outcome Prediction from Cardiovascular Multimodality Imaging by Artificial IntelligenceR35HL161195 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI Piotr J Slomka · 2022 to 2026
$5.0M
Integrating Artificial Intelligence for Optimal Analysis of CardiacPET/CTR01EB034586 · NIBIB · CEDARS-SINAI MEDICAL CENTER · PI DI CARLI, MARCELO F, SLOMKA, PIOTR J · 2022 to 2025
$2.9M
Cardiac Perfusion, Structure, and Function across the Primary Aldosteronism SpectrumK23HL159279 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Jenifer Michelle Brown · 2022 to 2026
$1.0M
Advanced CV imaging and immunophenotyping to study coronary vascular health in psoriasisK23HL159276 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI WEBER, BRITTANY NICOLE · 2021 to 2025
$962k
Interplay of Inflammation, Angiogenesis, and Coronary Microvascular Perfusion in Advanced Kidney DiseaseK23HL171893 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Michael Huck · 2025 to 2026
backgroundAbsolute quantification of myocardial blood flow (MBF) on positron emission tomography perfusion imaging improves the identification of coronary artery disease (CAD). However, distinguishing MBF impairment due to obstructive CAD from nonobstructive CAD remains challenging. We aimed to evaluate the incremental diagnostic value of positron emission tomography derived relative flow reserve (RFR) in the diagnosis of obstructive CAD.
methodsThis is a post hoc analysis of the multicenter phase III trial of
resultsThe study included 231 patients (71% male; 56% with established CAD) drawn from the original cohort of 755 trial participants. No patients had 3-vessel CAD. In a per-vessel-based analysis, 82% of vessels with reduced sMBF had no obstructive CAD on invasive coronary angiography. RFR was significantly lower for vessels with obstructive CAD (0.55 versus 0.80;
conclusionsRFR provides complementary diagnostic information beyond existing positron emission tomography parameters and may help refine the diagnosis of obstructive CAD in patients with reduced flows. REGISTRATION: URL: https://clinicaltrials.gov; Unique identifier: NCT01347710.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.